中国临床实用医学
中國臨床實用醫學
중국림상실용의학
CHINA CLINICAL PRACTICAL MEDICINE
2010年
8期
40-41
,共2页
胃癌%腹腔积液%热灌注化疗%替吉奥胶囊
胃癌%腹腔積液%熱灌註化療%替吉奧膠囊
위암%복강적액%열관주화료%체길오효낭
Stomach cancer%Malignant ascites%Chemohyperthermia%Gimeracil and Oteracil Porassium Capsules
目的 观察替吉奥胶囊联合腹腔灌注顺铂和白介素-Ⅱ治疗晚期胃癌所致腹腔积液近期疗效、临床受益率和副反应.方法 采用中心静脉导管以腹穿术行腹腔内置管,进行持续腹腔引流,引流量1000～1500 mL/d,引流3～5 d,而后经中心静脉导管注入含顺铂、白介素-Ⅱ的生理盐水200ml,48 h后打开引流管,引流残留腹水.从治疗第1天起口服替吉奥胶囊40～50 mg,2次/d,第1～28天,休息14d再进行下一周期治疗.共治疗2周期.结果 患者治疗后总有效率87.5%;临床受益率为90.6%.治疗副反应主要为骨髓抑制和消化道症状.结论 替吉奥胶囊联合腹腔灌注顺铂和白介素-Ⅱ治疗晚期胃癌所致腹腔积液,疗效确切,患者可耐受.
目的 觀察替吉奧膠囊聯閤腹腔灌註順鉑和白介素-Ⅱ治療晚期胃癌所緻腹腔積液近期療效、臨床受益率和副反應.方法 採用中心靜脈導管以腹穿術行腹腔內置管,進行持續腹腔引流,引流量1000～1500 mL/d,引流3～5 d,而後經中心靜脈導管註入含順鉑、白介素-Ⅱ的生理鹽水200ml,48 h後打開引流管,引流殘留腹水.從治療第1天起口服替吉奧膠囊40～50 mg,2次/d,第1～28天,休息14d再進行下一週期治療.共治療2週期.結果 患者治療後總有效率87.5%;臨床受益率為90.6%.治療副反應主要為骨髓抑製和消化道癥狀.結論 替吉奧膠囊聯閤腹腔灌註順鉑和白介素-Ⅱ治療晚期胃癌所緻腹腔積液,療效確切,患者可耐受.
목적 관찰체길오효낭연합복강관주순박화백개소-Ⅱ치료만기위암소치복강적액근기료효、림상수익솔화부반응.방법 채용중심정맥도관이복천술행복강내치관,진행지속복강인류,인류량1000～1500 mL/d,인류3～5 d,이후경중심정맥도관주입함순박、백개소-Ⅱ적생리염수200ml,48 h후타개인류관,인류잔류복수.종치료제1천기구복체길오효낭40～50 mg,2차/d,제1～28천,휴식14d재진행하일주기치료.공치료2주기.결과 환자치료후총유효솔87.5%;림상수익솔위90.6%.치료부반응주요위골수억제화소화도증상.결론 체길오효낭연합복강관주순박화백개소-Ⅱ치료만기위암소치복강적액,료효학절,환자가내수.
Objective To evaluate the efficacy and toxicity of Gimeracil and Oteracil Porassium Capsules combined with intraperitoneal perfusion chemotherapy for the patients of stomach cancer with malignant ascites. Methods Thirty-two patients of stomach cancer with malignant ascites were received the following treatment: infusing the 0.9% NS 200 ml of DDP and recomposed human interleukin- Ⅱ , then every patient took orally Gimeracil and Oteracil Porassium Capsules 40-50 mg/d, bid from the first day to twenth-eight day. Results The total response rate was 87.5% and the clinical benefition rate was 90.6%. The main toxicity was bone marrow suppression and gastroenteric. Conclusion The Gimeracil and Oteracil Porassium Capsules combined with intraperitoneal perfusion chemotherapy is well tolerated and effective in the patients of stomach cancer with malignant ascites.
